A Waltham-based biotech company is preparing to lay off about 75% of its staff, or 96 people, after it failed to secure key funding for a clinical trial. TScan Therapeutics will conduct the mass ...

Successful treatment of 91 patients with consistent safety and efficacy results observed to date; interim data to be presented at ESMO Congress in October 2026 – – Written feedback from FDA following ...

Caspian Therapeutics, is launching with $50 million in financing to develop menin inhibitors for diabetes and other ...

Trinovium to supply RTI with advanced fluids and analytical systems for deployment in a U.S. commercial pilot focused on AI and high-performance computing data center infrastructure Data center power ...

Top academic and healthcare institutions partner to build $500 million non-profit venture to turn promising biotech research ...

Biotech stocks are considered extremely high-risk, high-reward investments. Many biotech companies are developing one or more ...

Discover how Anneo Biotech, an Indian biotechnology leader, is building a cutting-edge microbiome ingredients platform for ...

They could both outperform the market over the medium term, but one appears to have a clear edge.

Months before the current biotech IPO boom, public investors began a more confident trek back into the sector, signaling the ...

The personal investment firms of titans like Stanley Druckenmiller are backing innovations in gene editing, drug discovery and more.

Discover the best biotech ETFs to diversify your portfolio, gain exposure to cutting-edge biotech innovations, and reduce risk in a volatile sector.

PDS Biotechnology Corporation ( PDSB) announced an equity financing of up to $22.55 million in a private investment in public equity (PIPE) transaction led by Nant Capital, LLC, with participation ...